Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma
ClinicoEconomics and Outcomes Research · 2025-04 · Volume 17 · 289-302
DOI: 10.2147/ceor.s501404 ↗Kurz gefasst
Fachartikel in der Zeitschrift ClinicoEconomics and Outcomes Research, 2025-04. Verfasst von Bhavesh Shah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Boston Medical Center, Boston, MA, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Boston Medical Center, Boston, MA, USA.
- Pfizer AB, Stockholm, Sweden.
- Cytel, Rotterdam, Netherlands.
- Oncohealth, Pompano Beach, FL, USA.
- Pfizer Inc, New York, NY, USA.
Zitieren
APA
Shah, B., Sandin, R., Liu, Y., Bobolts, L. R., Hu, Y., Mol, I., Schepart, A., Hughes, D. M., Hart, J., & Hlavacek, P. (2025). Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma. ClinicoEconomics and Outcomes Research, Volume 17, 289-302. https://doi.org/10.2147/ceor.s501404
Vancouver
Shah B, Sandin R, Liu Y, Bobolts LR, Hu Y, Mol I, et al. Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma. ClinicoEconomics and Outcomes Research. 2025;Volume 17:289-302. doi:10.2147/ceor.s501404
BibTeX
@article{Shah2025,
author = {Shah, Bhavesh and Sandin, Rickard and Liu, Yun and Bobolts, Laura R and Hu, Yannan and Mol, Isha and Schepart, Alexander and Hughes, David M and Hart, Jim and Hlavacek, Patrick},
title = {Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma},
journal = {ClinicoEconomics and Outcomes Research},
year = {2025},
volume = {Volume 17},
pages = {289--302},
doi = {10.2147/ceor.s501404}
}
EUVIMED